Therapeutics

#Biology #Cancer #Cancer research #Drug discovery #Therapeutics

Researchers develop novel therapy that could be effective in many cancers

Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery. The therapy is an engineered molecule called MS21 that causes the degradation of AKT, an enzyme that is overly… Read More

#Cancer Research #News #Trending News

#AI #Biology #R&D #Therapeutics #Tumour biology

Combining AI-driven drug capabilities with CDK targets for oncology

Exscientia and GT Apeiron Therapeutics have entered an R&D collaboration. Exscientia’s AI expertise will  be used to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. This collaboration follows the design of… Read More

#News

#Drug development #Drug innovation #Funding #Research #Therapeutics

Orbit Discovery plans growth in peptide discovery business

Orbit Discovery has raised US$7.6 million which will be used to accelerate its growth as a provider of peptide discovery services to the biotechnology and pharmaceutical industry. Orbit Discovery’s novel bead-based and microfluidic technology platform enables the screening of peptide libraries for target binding and subsequent activity in cell-based functional… Read More

#News

#Biosciences #Clinical trials #Drug delivery #Drug discovery #High throughput screening #Therapeutics

Mini-library approach delivers an arsenal in drug development pipeline

Listen to this article on the DDW Podcast: Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer Bioscience, a precision therapeutics company headquartered in Chengdu, China, explain how the company is identifying bioactive hits using libraries of less than 100 compounds. Read More

#Editor's Choice #Exclusive Content #News

#Biopharmaceuticals #Biotechnology #Drug development #Investment #Pharmaceuticals #Therapeutics

New laboratory boosts high-potency drug development

US-based Continuus Pharmaceuticals has opened a new laboratory space and new technology to help the development of high-potency drugs. The new lab and technology are the latest developments in Continuus’ ongoing expansion, coming six months after receiving a US$69.3 million US government contract for the domestic production of medicines. “Our… Read More

#News

#Covid-19 #Genomics #Infectious diseases #Therapeutics

Genomics analysis on why Covid-19 affects people so differently

Last year scientists from around the world undertook genetic analysis to uncover the genetic factors influencing why some Covid-19 patients develop severe, life-threatening disease requiring hospitalisation, while others escape with mild symptoms or none at all. A comprehensive summary of their findings to date, published in Nature, reveals 13 loci,… Read More

#Covid-19 #News #Trending News

#Biotherapeutics #Clinical research #Microbiome #Therapeutics

Report reveals the potential of microbiome-targeting therapeutics

GlobalData’s report, ‘Thematic Research: Microbiome-Targeted Therapeutics in Immunology’, reveals that 23 microbiome-targeting therapeutics are currently being developed in the US and the 5EU (France, Germany, Italy, Spain, UK) for gastrointestinal (GI), dermatological, and respiratory conditions. Each of these therapies aims to address these diseases by manipulating the microbiome. Microbiome is… Read More

#Market Reports #News #Trends & Analysis

#Biotherapeutics #Clinical trial #Clinical Trial Authorisation #Drug delivery #Drug development #Therapeutics

FDA Fast Track designation for Parkinson’s Disease treatment

BlueRock Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase I study. “Receiving Fast Track Designation from the FDA is an important step,… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Biotherapeutics #Covid-19 #Drug design #Drug development #Therapeutics

Exscientia accelerates Covid-19 drug discovery using AI

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the Covid-19 Therapeutics Accelerator initiative, to progress a new class of Covid-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform… Read More

#News

#Clinical trials #Events #Therapeutics

Ilya Pharma at US Military Health System Research Symposium

Ilya Pharma has been invited to present its ILP100 accelerated wound healing therapy at the US Military Health System Research Symposium (MHSRS) 2021, to be held August 23-26 at the Gaylord Convention Center in Florida. Results for the company’s first in human trial were released earlier this year and… Read More

#News

#Biomarkers #Drug development #Drug discovery #Neuroscience #Novel therapeutics #Therapeutics

Biomarker company raises £2.6 million for neuroscience drugs

Monument Therapeutics has raised £2.6 million in seed funding to spin out of Cambridge Cognition and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel… Read More

#News

#Biotechnology #Biotherapeutics #Clinical trials #Therapeutics

Starton Therapeutics features on Amazon Prime ‘Unicorn Hunters’

‘Unicorn Hunters’ is a new show on Amazon Prime which invites viewers around the world to invest alongside a panel of entrepreneurs and business leaders. It aims to level the field for start-ups who do not have access to traditional venture capital funding. The panel includes Steve Wozniak (Co-founder of… Read More

#News

#Cancer research #Drug development #Drug discovery #Drug innovation #Oncology #Research #Therapeutics

Sitting down with… Mari Scheiffele, Novartis

Mari Scheiffele is the General Manager for Oncology in the UK & Ireland at Novartis, responsible for launching innovative oncology therapies that can help to change the lives of people living with different types of cancer. She speaks to Lu Rahman about her passion for working with her teams to… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#AI #Drug development #Drug discovery #Novel candidates #Therapeutics

Strategic collaboration could open the door to new world-class medicines

EQRx and Exscientia are collaborating to combine the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates and expand EQRx’s pipeline of novel therapies. This collaboration is focused on creating improvements in the traditional drug discovery and development processes by improving the probability of success… Read More

#News

#Bioengineering #Biopharmaceuticals #Podcast #RNA #Therapeutics

Antibody engineering: why collaboration matters – podcast

The latest DDW Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. The company has created some successful partnerships and she explains what these look like, why… Read More

#News

#Drug development #Gene therapy #mRNA #Therapeutics

Evonik to develop new drug delivery platform for mRNA

Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). Starting in June 2021, Evonik and Stanford scientists begin a three-year sponsored research collaboration to develop the polymer-based drug delivery system, which Evonik will license… Read More

#News